Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.

Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS

Open source

DOI: 10.2147/jhc.s122507
Published: 2017
Container: Journal of hepatocellular carcinoma
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2147/jhc.s122507,
  title = {Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.},
  author = {Tarakanovskaya MG and Chinburen J and Batchuluun P and Munkhzaya C and Purevsuren G and Dandii D and Hulan T and Oyungerel D and Kutsyna GA and Reid AA and Borisova V and Bain AI and Jirathitikal V and Bourinbaiar AS},
  year = {2017},
  journal = {Journal of hepatocellular carcinoma},
  doi = {10.2147/jhc.s122507},
  url = {https://doi.org/10.2147/jhc.s122507}
}

RIS

TY  - JOUR
TI  - Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.
AU  - Tarakanovskaya MG
AU  - Chinburen J
AU  - Batchuluun P
AU  - Munkhzaya C
AU  - Purevsuren G
AU  - Dandii D
AU  - Hulan T
AU  - Oyungerel D
AU  - Kutsyna GA
AU  - Reid AA
AU  - Borisova V
AU  - Bain AI
AU  - Jirathitikal V
AU  - Bourinbaiar AS
PY  - 2017
JO  - Journal of hepatocellular carcinoma
DO  - 10.2147/jhc.s122507
UR  - https://doi.org/10.2147/jhc.s122507
ER  -

APA

MG, T., J, C., P, B., C, M., G, P., D, D., T, H., D, O., GA, K., AA, R., V, B., AI, B., V, J., & AS, B. (2017). Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.. Journal of hepatocellular carcinoma. https://doi.org/10.2147/jhc.s122507

Source records

pubmed · retrieved 2026-09-26T11:18:54.964Z